FFAR2 and inflammatory bowel disease: Given these findings, GPR43 seemed a likely candidate mediating the barrier-enhancing and anti-inflammatory properties of SCFA in IBD, and modulation of GPR43 is being investigated as a novel therapeutic strategy in the treatment of IBD.